MASCC Antiemesis Tool (MAT) APK

No rating yet

MAT is the first Android application for Cancer patients receiving chemotherapy... [readmore]


⇣ Download APK (4.09 MB)

This is an original APK file direct fetch from google play. It is safe to download and free of any virus.

Version 1.1.5
Update
Size 4.09 MB
Category Medical
Developer Helsinn Healthcare S.A.
Downloads ↓ 1.8K
⇣ Download APK (4.09 MB)

This is an original APK file direct fetch from google play. It is safe to download and free of any virus.

File Infos

License type Free
Version 1.1.5
Size 4.09 MB (4290350)
Filename com.helsinn.mat_2_4290350.apk
Requirement 4.2 and up
Type app
Category Medical
Package name: com.helsinn.mat
Slogan: MAT is the first Android application for Cancer patients receiving chemotherapy

APK Permissions


‣ 


APK used Features


‣ android.hardware.touchscreen

Screenshots (12 images)

MASCC Antiemesis Tool (MAT) screenshot 1 MASCC Antiemesis Tool (MAT) screenshot 2 MASCC Antiemesis Tool (MAT) screenshot 3 MASCC Antiemesis Tool (MAT) screenshot 4 MASCC Antiemesis Tool (MAT) screenshot 5 MASCC Antiemesis Tool (MAT) screenshot 6 MASCC Antiemesis Tool (MAT) screenshot 7 MASCC Antiemesis Tool (MAT) screenshot 8 MASCC Antiemesis Tool (MAT) screenshot 9 MASCC Antiemesis Tool (MAT) screenshot 10 MASCC Antiemesis Tool (MAT) screenshot 11 MASCC Antiemesis Tool (MAT) screenshot 12

About MASCC Antiemesis Tool (MAT) APK

MASCC Antiemesis Tool (MAT) poster
MASCC Antiemesis Tool (MAT) APK version 1.1.5 poster

Latest update [menu]


Content update

Description [menu]


Patients fighting cancer have to deal with Nausea and Vomiting, potential side effects related to chemotherapy. MASCC Antiemesis Tool (MAT) is the first Android application for Cancer patients receiving chemotherapy that helps their doctors in evaluating if and how much the anti-cancer treatment is causing nausea and vomiting.

The MASCC Antiemesis Tool (MAT) is a questionnaire developed and validated by the Multinational Association for Supportive Care in Cancer (MASCC), recognized as the leading Supportive Care Organization in the world. It consists of 4 questions on the intensity and frequency of nausea and/or vomiting after a chemotherapy session, during the first 24 hours and the delayed period (from the day after to 4 days after chemotherapy). By completing the MAT test from their Android devices, patients have the possibility to send the records to their doctors or nurses in real time. In this way the health care professional can promptly follow up and manage the symptom.

The App MAT Tool development was supported by an unrestricted grant from Helsinn Healthcare SA

How to install MASCC Antiemesis Tool (MAT) APK for Android [menu]


Download MASCC Antiemesis Tool (MAT) APK file (com.helsinn.mat_2_4290350.apk) from SameAPK.com, then follow these steps:

Update Phone Settings

  • Go to your phone Settings page
  • Tap Security or Applications (varies with device)
  • Check the Unknown Sources box
  • Confirm with OK

Go to Downloads

  • Open Downloads on your device by going to My Files or Files
  • Tap the APK file you downloaded (com.helsinn.mat_2_4290350.apk)
  • Tap Install when prompted, the APK file you downloaded will be installed on your device.

How to install MASCC Antiemesis Tool (MAT) APK on Windows 7/8/10 or MAC PC? [menu]


Download MASCC Antiemesis Tool (MAT) APK file(com.helsinn.mat_2_4290350.apk) from SameAPK.com to your PC (ex: /Users/xxx/Downloads/(com.helsinn.mat_2_4290350.apk)), then follow these steps:

Using Emulator:

  • Download And Install one Emulator Softwares (Ex: Bluestacks, GenyMotion, NoxPlayer)
  • Simple install APK on PC by drag and drop file com.helsinn.mat_2_4290350.apk on Emulator screen

MASCC Antiemesis Tool (MAT) APK Pros & Cons [menu]


Pros
  • This app is safe, it's not require high risk permissions
  • Compatible with 32 bit device (most Emulator using 32bit arch CPU)
  • Compatible with 64-bit device (some android device and current Bluestacks)

Cons
Everything is good.


Similar applications [menu]


New Apps



Comments

No comment Yet.